Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TSHA
TAYSHA GENE THERAPIES, INC.
NASDAQ
$5.77
▼ DOWN 3.19% (-0.19)

KEY STATISTICS

Market Cap$1.85 B
52w High$7.30
52w Low$2.71
Dividend Yield—
Frequency—
P/E-13.74
Volume2.07M
Shares Out.319.86M

COMPANY

LEADERSHIP

Sean Nolan
CHIEF EXECUTIVE
Sean Nolan

COMPENSATION 2026

Salary$645,840
Stock Awards$1,651,125
Incentive Plan Pay$542,506
All Other Comp.$1,169
Total$4,099,065

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 24, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
99

PRICE TARGET

Target High$15.00
Target Low$13.00
Target Median$14.00
Target Consensus$14.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$755.56K
NOV
3
TUE

PRICE

$5.77 ▼ DOWN 3.19% (−$0.19)
$5.63$5.70$5.78$5.859:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.77

About Taysha Gene Therapies, Inc.

https://www.tayshagtx.com ↗

Taysha Gene Therapies develops AAV-based gene therapies for monogenic CNS diseases, including treatments for Rett syndrome, CLN1, giant axonal neuropathy, SLC13A5 deficiency, and GM2 gangliosidosis, in partnership with UT Southwestern.

INDUSTRY

Biotechnology

A PRODUCT TAYSHA GENE THERAPIES, INC. IS KNOWN FOR

TSHA-102
TSHA-102

TSHA-102 is an investigational gene therapy for Rett syndrome, delivering a functional MECP2 gene via a one-time intrathecal treatment, currently in Phase 1/2 trials with FDA Breakthrough Therapy Designation.

COMPETITORS

COMPETITOR
NGNE COMPARE
PASG COMPARE
RGNX COMPARE
SRPT COMPARE
VYGR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
133
LISTED HERE
24
RANKED BY POSITION SIZE
VTS.AX
0.00% · 9.2M
IWM
0.05% · 6.2M
XBI
0.30% · 5.9M
SCHA
0.03% · 1.3M
FESM
0.09% · 1.0M
FYC
0.34% · 820.9K
SBIO
0.85% · 354.5K
XRSU.L
0.04% · 219.3K
LABU
0.20% · 215.7K
DFMC
0.01% · 128.1K
PRFZ
0.02% · 117.0K
RSSL
0.04% · 114.1K
BBC
0.62% · 54.9K
GSSC
0.03% · 52.5K
SGRW
0.72% · 35.5K
RFLR
0.07% · 12.3K
BIB
0.06% · 10.3K
TILT
0.00% · 10.0K
ESSC
0.15% · 9.4K
VETS
0.10% · 4.6K
TXS
0.05% · 3.5K
PQ
PQSG
0.20% · 1.1K
USFMDN.MX
0.00% · 901
RESM
0.05% · 465

INSTITUTIONAL OWNERSHIP

SHARES OWNED
65.58%
HOLDERS
242
TOP 12 OF 242 · RANKED BY POSITION SIZE
Rtw Investments, LP
24.4M sh · $79.64M
Ra Capital Management, L.P.
23.6M sh · $77.03M
Goldman Sachs Group Inc
22.4M sh · $99.99M
Avoro Capital Advisors LLC
21.7M sh · $97M
Morgan Stanley
19.3M sh · $63.14M
Blackrock, Inc.
18.6M sh · $102.54M
Vestal Point Capital, LP
18.0M sh · $80.46M
Fmr LLC
14.6M sh · $47.72M
Vanguard Group Inc
13.3M sh · $72.97M
Blackrock Inc.
11.7M sh · $26.3M
State Street Corp
11.2M sh · $50.1M
Siren, L.L.C.
11.0M sh · $36.02M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND HEAD OF R&D
Nagendran Sukumar
Sale · 200.0K shares
2026-07-10
★
DIRECTOR
Stalfort John A III
Purchase · 42.7K shares
2026-06-01
★
DIRECTOR
Stalfort John A III
Purchase · 21.3K shares
2026-06-01
★
DIRECTOR
Long Alison S
Purchase · 21.3K shares
2026-06-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 2
MARKET OUTPERFORM 1
OVERWEIGHT 1
9 GRADES IN THE LAST 12 MONTHS
Goldman Sachs BUY Citizens MARKET OUTPERFORM Needham BUY Baird OUTPERFORM BMO Capital OUTPERFORM B of A Securities BUY Canaccord Genuity BUY Chardan Capital BUY

SECTORS PEERS

PEERPRICE
DNTH$105.84COMPARE
ELVN$57.86COMPARE
ATAI$7.29COMPARE
NKTR$72.52COMPARE
XNCR$26.06COMPARE
ANAB$56.28COMPARE
IMTX$9.45COMPARE
SANA$3.93COMPARE